Gastric Cancer: Can Inhibitory Kappa B Kinases (IKKs) Predict Outcomes?
"New research explores how IKKs mRNA expression could serve as a prognostic tool for gastric cancer, offering potential targets for future therapies."
Gastric cancer remains a significant global health challenge, ranking as the fifth leading cause of cancer worldwide. Often diagnosed at advanced stages due to its asymptomatic nature, the prognosis for patients remains poor, with five-year survival rates estimated at less than 10%. Current treatment modalities include surgery, chemotherapy, and radiotherapy, with recent advancements in monoclonal antibodies offering promise as adjuvant therapies. However, there remains a critical need for novel therapeutic agents to improve patient outcomes.
Targeted therapies, exemplified by trastuzumab, have demonstrated success by leveraging advancements in understanding the mechanisms of carcinogenesis. These therapies, commonly used in breast cancer, target and inhibit human epidermal growth factor receptor 2 (HER2), gaining FDA approval for gastric cancer treatment in 2010. Another potential therapeutic target is the transcription factor NF-kB, implicated in cancer growth and progression, along with the pathways that facilitate its activation.
The transcription factor NF-kB plays a crucial role in modulating innate and immune responses to infection. Recent evidence highlights its potential in oncogenesis, promoting survival, proliferation, and invasiveness in cancer cells. The IKK family, comprising isoforms such as IKKa, IKKẞ, and regulatory subunits, plays a critical role in regulating the NF-kB cascade. These findings suggest that IKKs could represent viable prognostic predictors and therapeutic targets in gastric cancer.
Screening and Early Detection
A 2025 review describes gastric cancer as the fifth most commonly diagnosed malignancy and a leading cause of cancer-related deaths, and reports that five-year survival exceeds 90% when the disease is diagnosed at an initial stage. Current screening relies primarily on upper gastrointestinal endoscopy, which the review describes as highly accurate. A separate review evaluates the ABC classification system and notes a focus on the Helicobacter pylori-negative/pepsinogen-negative group, while the prognostic value of IKK expression in gastric cancer remains unclear.
From Early Surgery to Modern Research
The history of gastric cancer surgery includes Jules Emile Pean's first gastric resection for cancer on April 9, 1879, according to the historical account. A 2020 interdisciplinary study describes understanding the disease's pathogenic mechanisms as relatively recent and continuously updated, despite traces of its history in ancient civilizations. The National Cancer Institute's timeline presents selected milestones from 250 years of cancer research, while a related historical review characterizes progress since the first gastric surgery in 1879 as steps toward a more curable disease.
Decoding IKKs: What the Research Reveals About Gastric Cancer Prognosis
A recent study delved into the prognostic significance of inhibitory kappa B kinases (IKKs) mRNA expression in human gastric cancer. Researchers used the 'Kaplan-Meier plotter' (KM plotter) online database to assess the predictive value of individual IKKs members' mRNA expression concerning overall survival (OS). The analysis included diverse clinical data, such as pathological staging, histology, and therapies employed.
- IKKa: Higher mRNA expression correlated with better overall survival (OS).
- IKKẞ, IKKy, IKKɛ, and SIKE: Higher mRNA expression was generally associated with unfavorable OS in gastric cancer.
- IKKɛ: Increased mRNA expression showed better outcomes in stage IV gastric cancer.
- IKKɛ and SIKE: Elevated levels of mRNA expression correlated with favorable OS in diffuse-type gastric cancer.
- SIKE: High expression led to favorable OS when combined with adjuvant therapies but worsened OS when treated solely with 5FU therapy.
Recent Research and Reviews
A JAMA review dated January 7, 2026, summarizes current evidence on gastric cancer epidemiology, pathophysiology, diagnosis, and management. A recent report describes a potential strategy to overcome immunotherapy resistance in KRAS-mutant gastric adenocarcinoma, a subgroup said to account for approximately 10% of cases. The reported strategy combines KRAS inhibition with CTLA-4 blockade; the report links oncogenic KRAS to an immunosuppressive tumor microenvironment with reduced infiltration of cancer-fighting T cells.
Limits of Current IKK Evidence
A study of IKBKB rs2272736 reports that its findings support a role for IKBKB genetic associations in gastric tumorigenesis, but notes a limitation: the study involved a Han Chinese population of limited size. Another report says the clinical significance of NF-κB in gastric carcinoma remains unresolved because published information is limited and controversial, and notes a lack of data on its interaction with inhibitory protein IκBα in those cases. Bioinformatic analysis of IKK complex genes identifies in vitro functional testing in cell lines as a needed way to assess gene influences and cancer development or progression.
Contrasting Prognostic Signals
In a Kaplan–Meier plotter analysis, elevated IKKα mRNA was associated with better overall survival across all gastric cancer patients (HR 0.5, 95% CI 0.41–0.61; P=2e-12), and in intestinal-type (HR 0.39, 95% CI 0.28–0.54; P=4.6e-09) and diffuse-type disease (HR 0.58, 95% CI 0.41–0.83; P=0.0021). Separate studies examined NF-κB p65 activation in 63 surgically resected gastric carcinomas and NF-κB/RelA by immunohistochemistry in 290 specimens, but the supplied descriptions do not provide their outcome results for direct comparison. A 2024 study set out to compare efficacy and safety of S-1 plus oxaliplatin (S-1OX) with capecitabine plus oxaliplatin (CAPOX) in advanced gastric cancer, noting that it was unclear which therapeutic combinations were most beneficial.
Future Directions: Harnessing IKKs for Improved Gastric Cancer Treatment
This research underscores the potential of IKKs and SIKE as prognostic markers and therapeutic targets in gastric cancer. By understanding the distinct roles of these kinases, we can pave the way for more personalized and effective treatment strategies. Further investigation is warranted to fully elucidate the mechanisms underlying these associations and to translate these findings into clinical applications, ultimately improving outcomes for patients battling this challenging disease.
IKKs as Candidate Biomarkers
The cited article describes a recent study investigating the prognostic value of inhibitory kappa B kinase (IKK) mRNA expression in human gastric cancer. It says the findings point to potential biomarkers and therapeutic targets for improving patient outcomes. These are presented as potential applications, not established clinical tools.
Context-Dependent Effects of IKKβ Inhibition
A review of IKK inhibitors reports that IKKβ inhibition in some cells and tissues has been associated with spontaneous severe inflammatory conditions and, in some cases, malignant development. These observations suggest that NF-κB can have anti-inflammatory and tumor-suppressor roles in certain contexts. The review emphasizes that the consequences of IKKβ deletion and NF-κB inhibition depend strongly on cell type and context.
Real-World Immunotherapy Studies
A single-institutional retrospective study assessed nivolumab in a real-world clinical setting among patients with advanced gastric or esophagogastric junction adenocarcinoma. Participants had previously received first-line platinum-based doublet or triplet chemotherapy between 2010 and 2020. Separately, a 2025 real-world study of immune checkpoint inhibitor retreatment in advanced gastric cancer reported promising clinical benefit and manageable safety; a registry record describes another single-center retrospective observational study of patients treated at Zhengzhou University from January 2018 to July 2024.